HCM
AZN icon

Highbridge Capital Management’s AstraZeneca AZN Stock Holding History

Highbridge Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-75,000
Closed -$4.53M – 1309
2016
Q2 		$4.53M Buy
+75,000
New +$4.36M 0.07% 276

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Highbridge Capital Management's AZN Position: Q2 2018 in Review

Highbridge Capital Management sold out of AstraZeneca (AZN) in Q2 2018, closing a stake of 7,500 shares — an estimated $525K sold.

Highbridge Capital Management first reported a position in AZN in Q2 2016 and held it in 3 quarters. The position peaked at $8.44M in Q2 2016. 531 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

  • Highbridge Capital Management reported no remaining AstraZeneca position as of Q2 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 7,500 AstraZeneca shares in Q2 2018, an estimated $525K.
  • Highbridge Capital Management first reported a position in AstraZeneca in Q2 2016 and held it in 3 quarters.
  • Highbridge Capital Management's AstraZeneca position peaked at $8.44M in Q2 2016.
  • 531 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.